Literature DB >> 11298488

The role of tumour necrosis factor-alpha in the pathogenesis of complicated falciparum malaria.

M Odeh1.   

Abstract

Plasmodium falciparum malaria is the most important parasitic infection of humans and is one of the most serious health problems facing the inhabitants of developing countries. It is responsible for about 2 million deaths every year. To date there is no specific treatment for the disease apart from anti-malarials. The declining sensitivity to these drugs is a serious therapeutic problem, while no safe and effective vaccine is likely to be available for general use in the near future. There is now abundant laboratory and clinical evidence to suggest that tumour necrosis factor-alpha (TNF-alpha) plays a major role in the pathogenesis of complicated falciparum malaria. Modulation of TNF-alpha response in combination with the current anti-malarial drugs, may represent a novel approach to the treatment of the serious complications associated with the disease. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298488     DOI: 10.1006/cyto.2001.0845

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  11 in total

Review 1.  TNF ligands and receptors--a matter of life and death.

Authors:  David J MacEwan
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Genetic approaches to studying virulence and pathogenesis in Toxoplasma gondii.

Authors:  L David Sibley; Dana G Mordue; Chunlei Su; Paul M Robben; Dan K Howe
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-01-29       Impact factor: 6.237

3.  The role of pleural fluid-serum gradient of tumor necrosis factor-alpha concentration in discrimination between complicated and uncomplicated parapneumonic effusion.

Authors:  M Odeh; B Makhoul; E Sabo; I Srugo; A Oliven
Journal:  Lung       Date:  2005 Jan-Feb       Impact factor: 2.584

4.  Involvement of inflammatory chemokines in survival of human monocytes fed with malarial pigment.

Authors:  Giuliana Giribaldi; Mauro Prato; Daniela Ulliers; Valentina Gallo; Evelin Schwarzer; Oskar B Akide-Ndunge; Elena Valente; Silvia Saviozzi; Raffaele A Calogero; Paolo Arese
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

5.  TNF-alpha mediates the development of anaemia in a murine Trypanosoma brucei rhodesiense infection, but not the anaemia associated with a murine Trypanosoma congolense infection.

Authors:  J Naessens; H Kitani; Y Nakamura; Y Yagi; K Sekikawa; F Iraqi
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 6.  Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy.

Authors:  S Balachandar; A Katyal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-09       Impact factor: 3.267

7.  Lack of an association between antibodies to Plasmodium falciparum glycosylphosphatidylinositols and malaria-associated placental changes in Cameroonian women with preterm and full-term deliveries.

Authors:  Amorsolo L Suguitan; D Channe Gowda; Genevieve Fouda; Lucy Thuita; Ainong Zhou; Rosine Djokam; Simon Metenou; Rose G F Leke; Diane Wallace Taylor
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Possible influence of resistance to malaria in clinical presentation of rheumatoid arthritis: biological significance of natural selection.

Authors:  Fabio Bonilla-Abadía; Gabriel J Tobón; Carlos A Cañas
Journal:  Arthritis       Date:  2012-11-14

9.  Phagocytosis of haemozoin (malarial pigment) enhances metalloproteinase-9 activity in human adherent monocytes: role of IL-1beta and 15-HETE.

Authors:  Mauro Prato; Valentina Gallo; Giuliana Giribaldi; Paolo Arese
Journal:  Malar J       Date:  2008-08-18       Impact factor: 2.979

Review 10.  Hemozoin inhibition and control of clinical malaria.

Authors:  Chibueze Peter Ihekwereme; Charles Okechukwu Esimone; Edward Chieke Nwanegbo
Journal:  Adv Pharmacol Sci       Date:  2014-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.